Leerink Swann reaffirmed their buy rating on shares of Eli Lilly and Co. (NYSE:LLY) in a research report sent to investors on Sunday morning. The firm currently has a $103.00 target price on the stock.
Other equities analysts have also issued reports about the stock. Citigroup Inc. reiterated a buy rating on shares of Eli Lilly and in a report on Wednesday, August 3rd. Argus lifted their target price on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a buy rating in a report on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $93.00 target price for the company in a report on Friday, July 29th. BMO Capital Markets reissued a buy rating and set a $94.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 27th. Finally, Jefferies Group raised their price target on shares of Eli Lilly and from $100.00 to $105.00 and gave the company a buy rating in a research report on Thursday, July 14th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $97.06.
Shares of Eli Lilly and (NYSE:LLY) opened at 82.09 on Friday. The firm’s 50 day moving average price is $79.44 and its 200 day moving average price is $77.49. Eli Lilly and has a 52-week low of $67.88 and a 52-week high of $88.16. The stock has a market cap of $86.83 billion, a P/E ratio of 35.38 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same period last year, the business earned $0.90 earnings per share. The business’s revenue was up 8.6% on a year-over-year basis. On average, analysts expect that Eli Lilly and will post $3.59 EPS for the current year.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the sale, the insider now owns 1,300 shares in the company, valued at approximately $108,108. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total transaction of $16,703,400.00. Following the completion of the sale, the insider now owns 126,220,804 shares in the company, valued at approximately $10,039,602,750.16. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the company. Iowa State Bank bought a new stake in shares of Eli Lilly and during the second quarter valued at approximately $104,000. PineBridge Investments L.P. boosted its stake in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC acquired a new stake in shares of Eli Lilly and during the second quarter valued at about $117,000. Coconut Grove Bank boosted its stake in shares of Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock valued at $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. boosted its stake in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares in the last quarter. Institutional investors and hedge funds own 74.96% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.